CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Creative Medical Technology Holdings Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Creative Medical Technology Holdings Inc
211 E. Osborn Rd.
Phone: (480) 399-2822p:480 399-2822 PHOENIX, AZ  85012  United States Ticker: CELZCELZ
Business Summary
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. The Company conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Industries
SIC Code Description
3640 Electric lighting and wiring equipment
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer, Director TimothyWarbington 62 5/18/2016 5/18/2016
Chief Financial Officer, Senior Vice President, Director DonaldDickerson 58 5/18/2016 5/18/2016
Independent Director Michael H.Finger 76 12/2/2021 12/2/2021
Independent Director SusanSnow 66 12/2/2021 12/2/2021
Independent Director Bruce S.Urdang 65 12/2/2021 12/2/2021

Business Names
Business Name
AmnioStem LLC
CELZ
CELZD
5 additional Business Names available in full report.

General Information
Number of Employees: 4 (As of 12/31/2023)
Outstanding Shares: 1,356,626 (As of 3/22/2024)
Shareholders: 75
Stock Exchange: NASD
Federal Tax Id: 870622284


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, April 28, 2024